Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 24, 2024
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection
Curtis J Donskey, Erik R Dubberke, Nicola P Klein, et al.
The New England Journal of Medicine
|
September 15, 2021
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Ann R Falsey, Robert W Frenck, Edward E Walsh, et al.
Nature
|
August 14, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
The New England Journal of Medicine
|
October 14, 2020
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E Walsh, Robert W Frenck, Ann R Falsey, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 26, 2020
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Edward E Walsh, Robert Frenck, Ann R Falsey, et al.
Nature
|
January 20, 2021
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
The New England Journal of Medicine
|
May 27, 2021
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
Robert W Frenck, Nicola P Klein, Nicholas Kitchin, et al.
The New England Journal of Medicine
|
December 10, 2020
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Fernando P Polack, Stephen J Thomas, Nicholas Kitchin, et al.
The New England Journal of Medicine
|
September 15, 2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Stephen J Thomas, Edson D Moreira, Nicholas Kitchin, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 24, 2024
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection
Curtis J Donskey, Erik R Dubberke, Nicola P Klein, et al.
The New England Journal of Medicine
|
September 15, 2021
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Ann R Falsey, Robert W Frenck, Edward E Walsh, et al.
Nature
|
August 14, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
The New England Journal of Medicine
|
October 14, 2020
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E Walsh, Robert W Frenck, Ann R Falsey, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 26, 2020
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Edward E Walsh, Robert Frenck, Ann R Falsey, et al.
Nature
|
January 20, 2021
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
The New England Journal of Medicine
|
May 27, 2021
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
Robert W Frenck, Nicola P Klein, Nicholas Kitchin, et al.
The New England Journal of Medicine
|
December 10, 2020
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Fernando P Polack, Stephen J Thomas, Nicholas Kitchin, et al.
The New England Journal of Medicine
|
September 15, 2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Stephen J Thomas, Edson D Moreira, Nicholas Kitchin, et al.
Page
of 2